Priority Research Areas for Neurodegenerative Diseases

📖 Wiki Page

gap1250 wordssynced 2026-04-02

Priority Research Areas for Neurodegenerative Diseases

Last Updated: 2026-03-29 PT | Kind: gap-analysis | Section: gaps

Overview

flowchart TD gaps_priority_research_areas["Priority Research Areas for Neurodegenerative Di"] style gaps_priority_research_areas fill:#4fc3f7,stroke:#333,color:#000 gaps_priority_resear_0["Cross-Disease Research Priorities"] gaps_priority_research_areas -->|"includes"| gaps_priority_resear_0 style gaps_priority_resear_0 fill:#81c784,stroke:#333,color:#000 gaps_priority_resear_1["Tier 1: Highest Impact Score 35/40"] gaps_priority_research_areas -->|"includes"| gaps_priority_resear_1 style gaps_priority_resear_1 fill:#ef5350,stroke:#333,color:#000 gaps_priority_resear_2["Tier 2: High Priority Score 28-34"] gaps_priority_research_areas -->|"includes"| gaps_priority_resear_2 style gaps_priority_resear_2 fill:#ffd54f,stroke:#333,color:#000 gaps_priority_resear_3["Tier 3: Emerging Priorities Score 22-27"] gaps_priority_research_areas -->|"includes"| gaps_priority_resear_3 style gaps_priority_resear_3 fill:#ce93d8,stroke:#333,color:#000 gaps_priority_resear_4["Common Molecular Pathways Across Diseases"] gaps_priority_research_areas -->|"includes"| gaps_priority_resear_4 style gaps_priority_resear_4 fill:#4fc3f7,stroke:#333,color:#000 gaps_priority_resear_5["Protein Misfolding and Aggregation"] gaps_priority_research_areas -->|"includes"| gaps_priority_resear_5 style gaps_priority_resear_5 fill:#81c784,stroke:#333,color:#000

...

Priority Research Areas for Neurodegenerative Diseases

Last Updated: 2026-03-29 PT | Kind: gap-analysis | Section: gaps

Overview

Mermaid diagram (expand to render)

This page synthesizes cross-disease research priorities for neurodegenerative diseases, identifying areas where coordinated investment would have the highest impact across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington's disease (HD), and rarer proteinopathies. The goal is to highlight research areas with high potential for translation across multiple diseases, avoiding duplication with disease-specific priority lists found in [AD Knowledge Gaps Ranked](/gaps/ad-knowledge-gaps-ranked), [Parkinson's Knowledge Gaps](/gaps/parkinsons), and [ALS Knowledge Gaps](/gaps/als).

Cross-Disease Research Priorities

Tier 1: Highest Impact (Score ≥35/40)

| Priority | Research Area | Diseases | Why It Matters | Tractability |
|----------|---------------|---------|----------------|--------------|
| 1 | Protein aggregation mechanisms and strain diversity | AD, PD, ALS, FTD, HD, Prion | Common to nearly all neurodegenerative diseases; strains determine clinical phenotype and treatment response | High |
| 2 | Blood-based biomarker development for early detection | AD, PD, ALS, FTD | Enables prevention trials and early intervention; current biomarkers require invasive procedures | High |
| 3 | Selective neuronal vulnerability determinants | AD, PD, ALS, FTD | Explains why specific populations degenerate first; informs target discovery | Moderate |
| 4 | Neuroimmune modulation as therapeutic strategy | AD, PD, ALS | Microglia and astrocytes are key disease modifiers; TREM2, CD33, complement pathways implicated across diseases | High |
| 5 | Brain-body interaction pathways (gut-brain, immune-brain) | AD, PD, ALS | Emerging evidence that peripheral pathology influences CNS neurodegeneration | Moderate |

Tier 2: High Priority (Score 28-34)

| Priority | Research Area | Diseases | Why It Matters |
|----------|---------------|---------|----------------|
| 6 | Mechanisms of prion-like propagation across diseases | PD, ALS, FTD, AD | Templated protein misfolding may explain progressive spread; common therapeutic targets possible |
| 7 | Lysosomal and autophagy pathway dysfunction | PD, AD, ALS | GBA, GAA, C9orf72 mutations implicate clearance pathways; TFEB activation as therapeutic strategy |
| 8 | Mitochondrial dysfunction and energy failure | PD, ALS, AD | Energy deficit is a convergent feature; metabolic support as neuroprotective strategy |
| 9 | Genetic modifiers of penetrance and phenotype | PD, ALS, FTD, HD | Same mutation causes different diseases (e.g., MAPT, C9orf72); understanding modifiers enables precision medicine |
| 10 | Glymphatic and perivascular clearance mechanisms | AD, PD | Sleep-dependent clearance of toxic proteins; glymphatic enhancement as therapeutic approach |

Tier 3: Emerging Priorities (Score 22-27)

| Priority | Research Area | Diseases | Why It Matters |
|----------|---------------|---------|----------------|
| 11 | TDP-43 pathology in non-ALS diseases | ALS, FTD, AD, PD | TDP-43 inclusions found in many diseases beyond ALS; unified mechanism possible |
| 12 | Epigenetic regulation of neurodegeneration | AD, PD, ALS, HD | DNA methylation, histone modifications alter gene expression in disease; druggable targets |
| 13 | Metabolic syndrome and neurodegeneration intersection | AD, PD | Insulin resistance, diabetes modify disease risk and progression; GLP-1 agonists demonstrate metabolic neuroprotection |
| 14 | Cellular senescence in neurodegeneration | AD, PD, ALS | Senescent glia contribute to neuroinflammation; senolytics as therapeutic strategy |
| 15 | RNA metabolism and splicing alterations | ALS, FTD, AD | C9orf72 DPR proteins, TDP-43 mislocalization disrupt RNA processing |

Common Molecular Pathways Across Diseases

Protein Misfolding and Aggregation

Multiple neurodegenerative diseases share the feature of misfolded proteins forming toxic aggregates[@ryman2024]:

Amyloid-beta (Aβ): AD, cerebral amyloid angiopathy
Tau: AD, PSP, CBD, FTD, Pick disease
Alpha-synuclein: PD, DLB, MSA
TDP-43: ALS, FTD, limbic-predominant age-related TDP-43 encephalopathy (LATE)
Huntingtin: HD
Prion protein (PrP^Sc): CJD, FFI, GSS

Shared Downstream Mechanisms

Despite different initiating proteins, downstream pathways converge:

Calcium dysregulation: Disrupted calcium homeostasis affects mitochondrial function, synaptic transmission, and cell death pathways

Oxidative stress: Reactive oxygen species accumulate from mitochondrial dysfunction and metal dyshomeostasis

ER stress and UPR activation: Endoplasmic reticulum stress triggers apoptotic cascades

Inflammasome activation: NLRP3 and other inflammasomes mediate neuroinflammation

Axonal transport disruption: Impaired transport of organelles, proteins, and RNA along microtubules

Methodological Priorities

Biomarker Development Pipeline

| Stage | Biomarker Type | Priority Needs |
|-------|---------------|----------------|
| Discovery | Multi-omics (proteomics, metabolomics, lipidomics) | Large cohort collections, standardized protocols |
| Verification | CSF, plasma, serum assays | Assay validation, cross-platform standardization |
| Clinical validation | Longitudinal studies in prodromal populations | Regulatory-grade biomarker qualification |
| Deployment | Point-of-care or decentralized testing | Assay simplification, cost reduction |

Computational Approaches

Protein structure prediction: AlphaFold and successors for understanding mutant protein conformations
Network medicine: Mapping protein-protein interaction networks to identify hub vulnerabilities
Machine learning for biomarker discovery: Integrating multi-modal data (imaging, fluid, digital)
Digital phenotyping: Smartphone and wearable-derived motor and cognitive metrics

Translational Infrastructure

iPSC biobanks: Patient-derived cells for mechanistic studies and drug screening
Organoid models: 3D brain cultures recapitulating human development and disease
In vivo imaging: PET ligands for pathological proteins, synaptic function, and neuroinflammation
Clinical trial networks: Shared infrastructure across diseases for faster enrollment

Disease-Specific Priority Overlaps

Alzheimer's Disease / Parkinson's Disease Overlap

Alpha-synuclein/Tau co-pathology: Many patients have both pathologies; shared mechanisms and therapeutic targets
Neuroinflammation: Microglial activation patterns overlap; TREM2 variants affect both diseases
Sleep and circadian dysfunction: Common feature with bidirectional relationships

ALS / FTD Overlap (C9orf72 and TDP-43)

Hexanucleotide repeat expansion: Same C9orf72 mutation causes both ALS and FTD
TDP-43 pathology: Present in >95% ALS and ~50% FTD cases
Dipeptide repeat proteins: Non-conventional translation of repeats contributes to toxicity

Cross-Disease Genetic Modifiers

| Gene | Disease Associations | Mechanistic Link |
|------|---------------------|------------------|
| [TREM2](/genes/trem2) | AD, PD, ALS | Microglial phagocytosis and inflammation |
| [PTK2B](/genes/ptk2b) | AD, PD | Synaptic dysfunction and calcium signaling |
| [PLD3](/genes/pld3) | AD, PD | Amyloid processing and alpha-synuclein |
| [SNCA](/genes/snca) | PD, AD, DLB | Protein aggregation and synaptic function |
| [MAPT](/genes/mapt) | AD, PSP, CBD, FTD | Microtubule stability and tau pathology |

Therapeutic Target Priorities

Near-Term (Phase 2/3 trials ongoing or planned)

Anti-amyloid antibodies (lecanemab, donanemab, remternetug) — AD

GLP-1 receptor agonists (lixisenatide, semaglutide) — PD, AD

LRRK2 inhibitors (BIIB122/DNL151) — PD

Tau antibodies (E2814, semorinemab) — AD, PSP

SOD1/G93A antisense oligonucleotides — ALS

Medium-Term (Phase 1 or preclinical)

TDP-43-lowering therapies — ALS, FTD

alpha-synuclein antisense oligonucleotides — PD, DLB

GBA gene therapy and small molecule correctors — PD, Gaucher disease

NLRP3 inflammasome inhibitors — AD, PD, ALS

TFEB activators for autophagy enhancement — AD, PD, lysosomal storage disorders

Long-Term (Target validation needed)

Prion strain-specific therapeutics — Prion diseases

Huntingtin-lowering strategies — HD

Seneomorphic therapies (senolytics, senostatics) — Multiple diseases

Metabolic reprogramming agents — AD, PD

Epigenetic modulators (HDAC inhibitors, DNMT inhibitors) — AD, ALS, HD

Funding and Infrastructure Recommendations

Cross-disease biomarker consortia: Share samples, protocols, and data across AD, PD, ALS, FTD

Common control arm designs: Standardized placebo groups for faster trial enrollment

Repurposing screening platforms: Test AD drugs in PD models and vice versa

Regulatory harmonization: Align biomarker qualification across FDA, EMA, PMDA

Data sharing mandates: Require open-access data sharing as condition of funding

Cross-References to Disease-Specific Priority Pages

[Alzheimer's Disease Knowledge Gaps Ranked](/gaps/ad-knowledge-gaps-ranked)
[Parkinson's Disease Knowledge Gaps](/gaps/parkinsons)
[ALS Knowledge Gaps](/gaps/als)
[FTD Knowledge Gaps](/gaps/ftd)
[Huntington's Disease Knowledge Gaps](/gaps/huntingtons)
[Prion Disease Knowledge Gaps](/gaps/prion-disease)
[Shared Mechanisms in Neurodegeneration](/gaps/shared-mechanisms)
[Blood-Based Biomarkers for Early Detection Gap](/gaps/blood-based-biomarkers-early-detection)

References

📖 View canonical wiki page →